Kurosawa S, Stearns-Kurosawa D J, Hidari N, Esmon C T
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
J Clin Invest. 1997 Jul 15;100(2):411-8. doi: 10.1172/JCI119548.
The endothelial cell protein C receptor (EPCR) binds protein C and facilitates activation by the thrombin-thrombomodulin complex. EPCR also binds activated protein C (APC) and inhibits APC anticoagulant activity. In this study, we detected a soluble form of EPCR in normal human plasma. Plasma EPCR appears to be approximately 43, 000 D, and circulates at approximately 100 ng/ml (98.4+/-27.8 ng/ml, n = 22). Plasma EPCR was purified from human citrated plasma using ion exchange, immunoaffinity, and protein C affinity chromatography. Flow cytometry experiments demonstrated that plasma EPCR bound APC with an affinity similar to that previously determined for recombinant soluble EPCR (Kdapp = 30 nM). Furthermore, plasma EPCR inhibited both protein C activation on an endothelial cell line and APC anticoagulant activity in a one-stage Factor Xa clotting assay. The physiological function of plasma EPCR is uncertain, but if the local concentrations are sufficiently high, particularly in disease states, the present data suggest that the soluble plasma EPCR could attenuate the membrane-bound EPCR augmentation of protein C activation and the anticoagulant function of APC.
内皮细胞蛋白C受体(EPCR)能结合蛋白C,并促进凝血酶-血栓调节蛋白复合物对其的激活作用。EPCR还能结合活化蛋白C(APC)并抑制APC的抗凝活性。在本研究中,我们在正常人血浆中检测到了一种可溶性形式的EPCR。血浆EPCR的分子量约为43000道尔顿,其循环浓度约为100 ng/ml(98.4±27.8 ng/ml,n = 22)。采用离子交换、免疫亲和及蛋白C亲和层析法从人枸橼酸盐血浆中纯化血浆EPCR。流式细胞术实验表明,血浆EPCR结合APC的亲和力与先前测定的重组可溶性EPCR相似(Kdapp = 30 nM)。此外,在一阶段因子Xa凝血试验中,血浆EPCR既抑制内皮细胞系上蛋白C的活化,也抑制APC的抗凝活性。血浆EPCR的生理功能尚不确定,但如果局部浓度足够高,特别是在疾病状态下,目前的数据表明可溶性血浆EPCR可能会减弱膜结合型EPCR对蛋白C活化的增强作用以及APC的抗凝功能。